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Medulloblastoma (MB) is an embryonic brain tumour that arises in the cerebellum. Using several MB cell lines, we have
demonstratedthatthechemotherapeuticdrugetoposideinducesap53-andcaspase-dependentcelldeath.Wehaveobservedan
additional caspase-independent cell death mechanism involving delayed nuclear factor jB (NF-jB) activity. The delayed
induction was controlled bya p53-dependent transcription step andthe productionofdeathreceptors(especially CD95/Fas). We
further demonstrated that in both MB and glioblastoma (GM) cell lines, in which the p53 pathway was not functional, no p65
activationcouldbedetecteduponetoposidetreatment.MBcelllinesthathavemutationsinp53orNF-jBareeitherlesssensitive
(NF-jB mutant) or even completely resistant (p53 mutant) to chemotherapeutic intervention. The optimal cell death was only
achieved when both p53 and NF-jB were switched on. Taken together, our results shed light on the mechanism of NF-jB
activation by etoposide in brain tumours and show that the genetic background of MB and GM cells determines their sensitivity
to chemotherapy and has to be taken into account for efﬁcient therapeutic intervention.
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Medulloblastoma (MB) is the most common malignant brain
tumour in children.
1 It is a primitive neuro-ectodermal tumour,
arising from neural stem cell precursors in the granular cell
layer of the cerebellum. Current treatments include different
combinations of surgical resection, craniospinal radiotherapy
and chemotherapy. The survival rate as a function of the
tumour stage is between 60 and 80%. However, despite the
efﬁciency of current treatments, survivors still suffer signiﬁ-
cant long-term after-effects and children younger than 3 years
old have a less favourable prognosis as some therapy
modalities are not possible.
2 Etoposide is one of the currently
used clinical chemotherapeutic agents. It damages DNA by
stabilising the DNA-topoisomerase II complex, thus increas-
ing the frequency of double-stranded DNA breaks. However,
tumours display different sensitivities to this drug and the
molecular mechanisms of resistance are largely unknown.
Etoposide has previously been shown to activate the
proinﬂammatory nuclear factor kB (NF-kB)-dependent signal-
ling pathway,
3,4 the tumour suppressor p53 transcription
factor,
5 as well as the death receptor (DR) Fas expression.
6
NF-kB is a family of transcription factors; RelA/p65, the main
member of the canonical pathway is involved in inﬂamma-
tion,
7 cell cycle progression
8 and tumorigenesis.
9 Yet the
effects of its activity are blurred because of its dual role as a
pro- or antiapoptotic factor.
10 Its role in cell death has
previously been reported in several cellular models including
neuroblastoma.
11,12 p53 responds to DNA damage or de-
regulation of mitogenic oncogenes through the induction of
cell cycle arrest, apoptosis or cellular senescence. Mutations
in p53 are often associated with aggressive tumour behaviour
and poor patient prognosis.
13
Previous investigations have indicated potential crosslink
between p53 and NF-kB pathways, but relatively few studies
explore the molecular mechanisms involved. The best
described mechanisms of crosstalk are (1) direct competitive
interaction between p53 or p65 with the transcriptional
coactivator proteins p300 and CREB-binding protein
(CBP),
14–16 and (2) the recruitment of the non-canonical
NF-kB member p52 by p53 and subsequent regulation of
p53-dependent genes.
17 We demonstrate here, for the ﬁrst
time, a new molecular bridge between NF-kB and p53 that
involves transcription and expression of DRs. The DR family
includes Fas(CD95/APO-1), deathreceptor 3–6(DR3–6) and
tumour necrosis factor-R1 (TNF-R1) receptors. A shared
feature of DRs is a conserved 80 amino-acid sequence, the
death domain, in the cytoplasmic tail of these molecules.
Received 26.10.09; revised 22.3.10; accepted 26.3.10; Edited by A Verkhrasky
1Centre for Cell Imaging, School of Biological Sciences, University of Liverpool, Liverpool L69 7ZB, UK and
2Alder Hey Children’s NHS Foundation Trust, Liverpool L12
2AP, UK
*Corresponding author: V Se ´e, Centre for Cell Imaging, School of Biological Sciences, University of Liverpool, Liverpool L69 7ZB, UK.
Tel: þ44 151 795 4598; Fax: þ44 151 795 4404; E-mail: violaine@liverpool.ac.uk
Keywords: medulloblastoma; glioblastoma; NF-kB; p53; CD95/Fas; DNA damaging agents
Abbreviations: CBP, CREB-binding protein; DR3–6, death receptor 3–6; EGFP, enhanced green ﬂuorescent protein; FADD, Fas-associated via death domain; FasL,
Fas ligand; GM, gliobastoma; IkBa, inhibitor of nuclear factor kBa; IKK, IkB Kinase; MB, medulloblastoma; mdm2, mouse double minute 2; NF-kB, nuclear factor kB;
PFTa, piﬁthrin-a; TNFa, tumour necrosis factor-a
Citation: Cell Death and Disease (2010) 1, e41; doi:10.1038/cddis.2010.16
& 2010 Macmillan Publishers Limited All rights reserved 2041-4889/10
www.nature.com/cddisUpon activation of Fas, sequential association of the adaptor
molecule Fas-associated via death domain (FADD) and pro-
forms of caspase 8 lead to the death signalling.
18
We have observed a delay in p65 activation following
etoposide treatment compared with the classical TNFa
activator, due to an essential transcription/translation mecha-
nism.Wehavefurtheridentiﬁedp53andFasaskeymediators
ofthisactivityinMBcells.WehaveuseddifferentMBcelllines
(D283-MED, MHH-Med1, MEB-Med8A and D458-MED cells)
that bear differential mutation status in the NF-kB and/or p53
genes, and showed that they are correlated to differential
sensitivity to chemotherapeutic treatment. Similar results
were obtained in some glioblastoma (GM) cell lines (D566-
MG, U87MG and T98G cells). Altogether our data strongly
suggest a clear molecular mechanism for etoposide-induced
cell death in brain tumours, which ought to be
taken into account to maximise the efﬁciency of clinical
management.
Results
Etoposide induces a delayed p65 activation in MB
cells. Etoposide has previously been shown to activate
p65.
3,19 We have probed this activation in MB cells by
western blot with an anti-phospho-Ser536 p65 antibody. We
observed p65 phosphorylation 6h after etoposide treatment
in D283-MED and D458-MED cells. Interestingly, this
phosphorylation was not observed in MHH-Med1 or in
MEB-Med8A cell lines (Figure 1a). This phosphorylation
event was further correlated with p65-dependent
transcription. Using luminometry, we have shown that only
D283-MED and D458-MED cells displayed an etoposide-
induced NF-kB-dependent transcriptional activity (Figure 1b).
As a positive control, TNFa was used to show that
NF-kB could be induced in these cells. It was found that
MHH-Med1 cells did not respond to TNFa, but all of the other
three cell lines showed the expected NF-kB response
(Figure 1d and e and Supplementary Figure S1A–C).
Despite the observation that Ser536 phosphorylation is
essential for p65 activity, we further analysed the absence
of NF-kB induction upon TNFa treatment in MHH-Med1 cells.
We showed that 10ng/ml of TNFa was unable to induce
inhibitor of nuclear factor kBa (IkBa) degradation, p65
nuclear translocation and NF-kB-dependent transcription
(Supplementary Figure S1D–F).
We then used the D283-MED cells as a model cell line and
probed the role of IkB Kinases (IKKs) and IkBa in etoposide-
induced p65 phosphorylation. Treatment of D283-MED cells
with the IKKs inhibitor BMS-345541 or IkBa inhibitor Bay11-
7082 inhibited etoposide-induced p65 phosphorylation
(Figure 1c), showing the essential function of IKKa/b and
IkBa in etoposide-induced p65 signalling. The dynamics of
p65 activation and translocation into the nucleus were also
examined using time-lapse confocal microscopy of single
living cells transfected with vectors encoding p65-RedXP and
IkBa-enhanced green ﬂuorescent protein (EGFP) ﬂuorescent
fusion proteins (Figure 1d). As previously demonstrated in
other cell lines,
4,20 we observed damped p65 nuclear-
cytoplasmic oscillations after TNFa treatment. The ﬁrst peak
of nuclear occupancy was at B60min after TNFa treatment.
Following etoposide treatment, p65 translocation into the
nucleus was delayed by 1h and the peak amplitude was
reduced (Figure 1d). The delay in p65 activation was
conﬁrmed by western blotting (Supplementary Figure S1A)
and by luminescence imaging (Figure 1e) using a
NF-luciferase reporter vector containing 5 repeats of NF-kB-
binding sites cloned upstream of the luciferase gene. The
presence of a delay suggested that p65 activation might be
indirect. To determine if the delay was caused by an earlier
transcriptional and/or translational event, we inhibited tran-
scription with actinomycin-D (Figure 1f) or translation with
cycloheximide (Supplementary Figure S2) 30min before
TNFa/etoposidetreatment.Etoposide-inducedp65phosphor-
ylationwaspreventedbybothinhibitors,suggestingthataﬁrst
transcription/translation event was essential for etoposide-
induced p65 activation. As expected, the inhibition of
transcription/translation did not affect TNFa-induced p65
phosphorylation.
Medulloblastoma cell lines displayed different
sensitivity to etoposide involving both caspase-
dependent and -independent programmes. The effect of
etoposide on cell viability in different MB cell lines was
assessed using the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay
(Figure 2a). This showed that these cell lines displayed a
different sensitivity to etoposide treatment. We observed
B80% of cell death 24h after treatment in both D283-MED
and D458-MED cells, whereas MHH-Med1 displayed only
58% of death at the same time. Conversely, MEB-Med8A
cells were strongly resistant to etoposide treatment up to
24h. We next investigated the role of p65 activity in the cell
death programme activated by etoposide. Inhibition of NF-kB
pathway in D283-MED cells was obtained either with various
NF-kB inhibitors (Wedelolactone: IKK complex inhibitor;
Bay11-7082: IkBa inhibitor; JSH-23: p65 nuclear trans-
location inhibitor) or by using p65 siRNA. This inhibition
partially or totally prevented etoposide-induced cell death
(Figure 2b and c), suggesting a key role for NF-kBi n
etoposide-induced cell death in these cells. Similar results
were obtained for D458-MED cells (not shown). In contrast,
MHH-Med1 cells (in which no p65 activity could be detected)
were not protected by NF-kB inhibition (Supplementary
Figure S3A).
To further characterise the type of cell death induced by
etoposide, we measured the caspase 3/7 activity in each cell
line (Figure 2d). In accordance with the viability assay, we
observed strong and fast caspase-3 activation in D283-MED
and D458-MED cells; however, no caspase-3 activation could
be observed in MEB-Med8A until 24h after etoposide
treatment. This was in line with the resistance of this cell line
to etoposide-induced cell death. Surprisingly, MHH-Med1
cells displayed a stronger caspase activity compared with
D283- and D458-MED cells, although lower cell death was
observed in these cells (Figure 2a and d). This suggests the
involvement of a different cell death mechanism, which was
independent of caspase-3 activation. Evidence to support this
hypothesis was that blocking NF-kB activity with Bay11-7082
did not prevent caspase-8 or 3/7 induction (Figure 2e), but
p53-dependent NF-jB activation by etoposide
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Cell Death and Diseaseprotected the cells from etoposide cytotoxicity (Figure 2b).
These data suggest that p65 may be involved in a caspase-
independent cell death pathway that may enhance another
form of etoposide-induced caspase-dependent cell death.
Etoposide-induced cell death was further characterised by an
annexin V–propidium iodide assay and we observed by ﬂow
cytometry both apoptosis and necrosis (not shown). An assay
of macroautophagy induction by acidic vacuoles staining with
the monodansylcadaverine dye suggested some autophagy
induction (Supplementary Figure S4).
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Figure 1 Etoposide induces a delayed p65 activation in some MB cells. (a) Four MB cell lines were treated with 20mM etoposide for 6h. p65 and p65-Ser536
phosphorylation levels were assessed by western blot. The blot presented is representativeof three independentexperiments.Quantiﬁcationof the bands was plotted as p65
phosphorylation fold increase compared with the control non-treated cells. (b) After 24h transfection with NF-luc plasmid, cells were treated with 20mM etoposide for 8h
before assessment of the luciferase activity. Relative luminescence measurements to t0 are plotted for each cell line. (c) D283-MED cells were simultaneously treated for 6h
with 20mM etoposide and 5mM Bay11-7082 or 10mM BMS-345541. p65 phosphorylation was analysed by western blot. The blot presented is representative of three
independent experiments and the plot represents the quantiﬁcation of the blot shown. (d) D283-MED cells transfected with p65-RedXP and IkBa-EGFP were treated with
20mM etoposide or 10ng/ml TNFa. Time-lapse confocal microscopy was performed as described in Materials and Methods. Mean ﬂuorescence intensities for individual cells
wereanalysed.Atypicalcellforeachtreatmentwasplottedasthep65nuclear/cytoplasmicratioasafunctionoftime.(e)D283-MEDcellstransfectedwithNF-Lucvectorwere
treated with 20mM etoposide or 10ng/ml TNFa. Real-time luminescence signal was captured as described in Materials and Methods. The graph represents mean
luminescence intensities measured in whole ﬁeld. (f) D283-MED cells were pretreated 30min with 5mg/ml of the transcription inhibitor actinomycin-D, prior to a 10min
treatment with 10ng/ml TNFa, or a 4h treatment with 20mM etoposide. p65 phosphorylation levels were analysed by western blot. The blot presented is representative of
three independent experiments and the plot represents the quantiﬁcation of the blot shown
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Cell Death and Diseasep53 is required for etoposide-induced p65 activity in MB
cells. We have shown that transcription and translation were
required for delayed p65 activation and subsequent NF-kB-
dependent death (Figure 1f and Supplementary Figure S2).
As etoposide causes DNA damage, an obvious candidate
intermediate is p53, the main DNA damage sensor. Previous
work in neuroepithelial cells had suggested that etoposide
induces cell death in p53-dependent manner.
21 Indeed,
etoposide treatment induced an accumulation of p53
protein in D283-MED, D458-MED and MHH-Med1 cells
(Figure 3a). However, MEB-Med8A cells expressed a low
level of p53wt, but a p53 isoform or truncated form was
detected by Western blot with an additional band being
evident at a slightly lower molecular weight. The
accumulation of p53 in the three other cell lines was further
correlated with the induction of p53-dependent transcription
as shown by quantitative RT-PCR (qPCR) detection of the
mouse double minute 2 (mdm2) transcripts (Figure 3b). We
then investigated if p53 could be the upstream factor involved
in the delayed p65 activation. Both invalidation of p53
expression using siRNA and treatment of D283-MED cells
with Piﬁthrin-a (PFTa), a well-described p53 inhibitor,
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Figure 2 MB cell lines displayed different sensitivity to etoposide involving both caspase-dependent and -independent cell death. (a) Cell viability was analysed by MTS
assay at indicated time points, upon 20mM etoposide treatment. (b) Viability of D283-MED cells treated with 20mM etoposide in the presence of 5mM Bay11-7082, 10mM
Wedelolactone or 5mM JSH23 was assessed by MTS assay. (c) D283-Med cells were transfected with 100nM of siRNA directed against p65 or a control scrambled siRNA.
After 48h, cells were treated with 20mM etoposide for 8h and viability was assessed by MTS assay. The knockdown efﬁciency was controlled by western blot (insert).
(d) Several MB cell lines were treated with 20mM etoposide for indicated times. Caspase 3/7 activity was measured with Caspase-Glo 3/7 assay kit. Results are expressed
as fold-induction compared with control non-treated cells as a function of time. (e) D283-MED cells were treated with 20mM etoposide in presence or absence of 5mM
Bay11-7082 for 8h. Caspase 8 and 3/7 activities were assessed with Caspase-Glo assay kits. Results are relative to control non-treated cells. a–d results are the mean of
three independent experiments±S.E.M. ‘***’ indicates statistical difference with Po0.001
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Cell Death and Diseasestrongly inhibited etoposide-induced p65 phosphorylation
(Figure 3c and Supplementary Figure S5). Moreover,
although the NF-kB pathway responded normally to TNFa
in MEB-Med8A cells (Supplementary Figure S1C), the
absence of etoposide-mediated p65 phosphorylation
(Figure 1a) was most likely due to the absence of p53wt
(Figure 3a) in these cells. We then demonstrated the role of
p53 in etoposide-mediated cell death and in caspase
activation. Invalidation of p53 expression using siRNA
totally protected D283-MED cells (Figure 3d) and MHH-
Med1 cells (Supplementary Figure S3B) to drug cytotoxicity
and signiﬁcantly inhibited caspases 8 and 3/7 activities
(Figure 3e and Supplementary Figure S3C). These results
indicated that p53 induction was a prerequisite for two
distinct death pathways triggered by etoposide: one that was
caspase-dependent and the other that was p65-dependent
but caspase-independent.
The expression of Fas DR is required for p65
phosphorylation. To further elucidate the link between
p53-dependent transcription and p65 activity, we have
screened by qPCR several p53-dependent genes upon 6h
of etoposide treatment. We observed in D283-MED, D458-
MED and MHH-Med1 cells an induction of several DRs
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Cell Death and DiseasemRNA, DR3, DR4, DR5 and more strongly Fas receptor
mRNA (Figure 4a). Conversely, no transcription was induced
in MEB-Med8A cells, where the p53 pathway was found to be
mutated. The high levels of Fas receptor transcripts were
reﬂected in the expression of the receptor at the plasma
membrane in D283-MED and MHH-Med1 cells as measured
by immunocytochemistry and ﬂow cytometry (Figure 4b and
c and Supplementary Figure S6A). In addition p53
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Cell Death and Diseaseknockdown by siRNA impaired expression of Fas receptor
(Figure 4d and Supplementary Figure S6B). We then
investigated the role of Fas receptor in p53/p65 crosstalk.
D283-MED cells were transfected with a Fas siRNA for 48h
and treated with etoposide for an additional 6h. Fas receptor
knockdown strongly inhibited p65 phosphorylation
(Figure 4e). To probe in detail the mechanism of Fas
activation, we inhibited the interaction between Fas receptor
and its ligand (FasL). However, treatment with the Fas
antagonist antibody ZB4 or the inhibitory peptide Kp7-6 did
not inhibit etoposide-induced cell death (Figure 4f and
Supplementary Figure S7A, B) or p65 phosphorylation
(Figure 4g and Supplementary Figure S7C). These results
suggested that Fas receptor-induced p65 activation was
independent of FasL. This ﬁnding was conﬁrmed by the
absence of FasL ampliﬁcation by qPCR (Supplementary
Figure S7D) and by the fact that no FasL could be detected
by ELISA (not shown). Interestingly, similar observations
have been described in other MB cell lines
22 and suggest an
important role of receptor oligomerisation in Fas receptor
activity.
The upstream role of p53 in cell death sensitivity also
takes place in GM cells. To probe the generality of our
ﬁndings in other central nervous system tumour cells,
further experiments were performed in GM cell
lines (D566-MG, T98G and U87MG cells). Interestingly,
different sensitivities were also observed upon etoposide
treatment (Figure 5a), and were again correlated with the
activation status of p53 and NF-kB signalling pathways.
Indeed, D566-MG and T98G GM cells were found to be
unable to accumulate p53 after etoposide treatment
(Figure 5b) and consequently no Fas expression
(Figure 5c) or p65 phosphorylation (Figure 5b) could be
detected. The impairment in p53- and p65-dependent
signalling was also conﬁrmed by the absence of induction
of speciﬁc target genes (mdm2 and IkBa, Figure 5c). These
cells were strongly resistant to etoposide-induced cell death
as previously observed with the MB MEB-Med8A cells
(Figures 2a and 5a). U87MG GM cells showed p53
accumulation (Figure 5b) and Fas transcription (Figure 5c)
upon etoposide treatment. However, similarly to the MB
MHH-Med1 cells, no p65 activation was detected (Figure 5b
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Figure 5 The upstreamrole of p53in cell death sensitivityis also valid in glioblastoma cells. (a) Cell viability was analysedin severalglioblastoma cell lines by MTS assay
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(Figure 5a). In contrary to the MHH-Med1 cells, the absence
of p65 activation in U87MG is not due to an impairment of the
NF-kB pathway, as TNFa treatment was able to induce IkBa
degradation, p65 phosphorylation and translocation into the
nucleus (Figure 5d and Supplementary Figure S8). The two
other GM cell lines (D566-MG and T98G) displayed a normal
p65 activation and IkBa degradation upon TNFa stimulation
similarly to MEB-Med8A cells (Figure 5d and Supplementary
Figure S8).
The role of p53, Fas and p65 and the consequences on cell
death of mutations at different levels of the signalling cascade
in both MB and GM cells are summarised in the diagram
Figure 6.
Discussion
Delay in NF-jB induction by etoposide, role of the
p65-p53 crosstalk. Our results describe a new mechanism
of crosstalk between the p53 and NF-kB signalling pathways
through DRs production. This ﬁnding may also explain the
mechanism by which MB cell lines show differential
resistance to etoposide treatment. Previous studies in
leukaemia and neuroblastoma cells have described
etoposide-induced NF-kB activation.
4,19,23 In those studies
NF-kB inhibition was enhancing etoposide-induced apop-
tosis, whereas we show here a protection of MB cells using
three different NF-kB inhibitors acting at different levels of
the signalling pathway or by p65 knockdown with siRNA.
This role of NF-kB in triggering cell death has previously
been observed in osteosarcoma cell line.
12 The difference
suggests a tumour-dependent role of p65.
A delayed NF-kB activation has previously been reported
using two different stimuli (etoposide and FasL),
19,24 although
the mechanism of this delay was not described. The NF-kB
activation observed in this study indicates the involvement of
IKKa/b and IkBa (Figure 1c) as both BMS-345541 and Bay11-
7082 inhibited etoposide-induced p65 phosphorylation.
Furthermore, inhibition of either transcription or translation
also prevented p65 activation and we have identiﬁed p53 and
Fas receptor as key upstream proteins. p65-p53 crosstalk
has previously been reported. A direct competition with the
CBP/p300 proteins,
14–16 whereby p53 down-regulates NF-kB
transcription is well documented. This cannot be the case in
thesystemstudiedhereas:(1)p53inhibitionabolishedNF-kB
activation (Figure 3c and Supplementary Figure S5); and
(2) no NF-kB activity could be detected in cells were p53 was
defective (MEB-Med8A cells). Bohuslav et al.
25 have sug-
gested another mechanism, in which p53 activation is able to
induce Ser536 p65 phosphorylation and nuclear translocation
throughtheribosomalS6 Kinase1 (Rsk1).Thisisproposedto
be independent of IKK activation and IkBa degradation. We
cannot exclude the implication of Rsk1 in our model, yet it is
unlikely to be of primary importance as (1) the etoposide-
induced p65 phosphorylation is dependent of IKKs activity
(Figure 1c), (2) We have observed IkBa degradation following
etoposide treatment (not shown) and (3) p65 activation is
dependent on a transcriptional event (Figure 1f). This was not
the case in the results reported by Bohuslav et al.
25
Etoposide-induced NF-kB activation appeared to be weak-
er than that from TNFa stimulation as judged by a lower
nuclear translocation amplitude and level of phosphoryla-
tion
19 (Figure 1d and Supplementary Figure S1A) and
indicates that other mechanisms than the ones occurring
upon TNFa stimulation are involved. It could be argued that
the observed NF-kB activation might in turn modulate p53
activity as a negative feedback loop.
26 This hypothesis was
tested by siRNA knockdown of p65 and no change in
etoposide-dependent p53 activation was observed (Supple-
mentary Figure S9). However, the cross-regulations between
the NF-kB and p53 are likely to be highly complex and
dynamic and could also be more subtle and dependent on the
stimuli.
Death receptors as a bridge between p53 and NF-jB. It
has been previously shown in vascular smooth muscles
cells that p53 can induce a rapid expression of Fas to the
plasma membrane from the Golgi, without new RNA and
protein synthesis.
27 However, we have here observed a
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Figure 6 Molecular mechanisms of etoposide-induced cell death in brain
tumours. The schematic diagram represents a model of intracellular mechanism
induced by etoposide in both GM and MB cells. Depending on the genetic
background, cells display different sensitivity to etoposide. Through its genotoxic
function,etoposideinducesp53activation.p53activatesthetranscriptionof various
genes involved in regulation of cell cycle arrest and cell death as Fas receptor and
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FasL-independent manner as well as a caspase-dependent apoptotic cell death.
p65 enhances apoptotic death by inducing a caspase-independent cell death. Cells
displaying this fully efﬁcient crosstalk are very sensitive to etoposide-induced cell
death (D283-MED, D458-MED). Conversely, cells impaired in p53 activation are
strongly resistant to cell death (MEB-Med8A, D566-MG, T98G). Interestingly, Cells
displaying p53 activity but an impaired p65 activation show intermediate resistance
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grey-to-black gradient illustrates the sensitivity to etoposide-induced cell death. The
dotted red lines represent the nods in transduction pathways that are blocked in
indicated cell lines
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(Figure 4d).
An interesting ﬁnding is the involvement of the DR in a
ligand-independent manner. We used two different
approaches using the speciﬁcity of the antagonist antibody
ZB4 and the antagonist peptide Kp7-6 (Figure 4f and g and
SupplementaryFigure S7).We showednoeffects ofinhibition
ofFas–FasLinteractiononetoposide-mediatedcelldeathand
p65 activation. We therefore checked the presence of FasL
expression by ELISA and qPCR. Surprisingly, we did not
detect any increase of FasL expression upon etoposide
treatment; moreover, we did not detect any basal expression
either, compared with two other human cancer cell lines
(Supplementary Figure S7D). However, the Fas receptor
knockdown by siRNA completely inhibited the etoposide-
induced p65 phosphorylation (Figure 4e). Altogether,
these results suggest that the strong overexpression of
Fas induces a ligand-independent oligomerisation allowing
the activation of downstream signalling. It was commonly
thought that membranous receptors were in a monomeric
form at the membrane, and that oligomerisation was induced
by the ligand. However, it has been shown that TNF receptor
family members can assemble in a ligand-independent
manner to form a preoligomerised complex at the plasma
membrane.
28 In addition, more recent work has shown a
similar process, in which Fas was able to induce ligand-
independent signalling.
29 We have also shown that the
overexpression of Fas receptor was sufﬁcient to induce
cell death in D283-MED but not in MHH-Med1 cells
(Supplementary Figure S10).
Despite few studies describing a caspase-dependent
inhibitory effect of Fas on NF-kB,
30,31 it is usually accepted
that Fas induces NF-kB.
24,32 This activation involves the
adaptor protein FADD, caspase-8 and RIP. Although FADD is
likely involved in our signalling cascade, the role of caspase-8
is less clear as caspase-8 inhibition did not inhibit p65
phosphorylation (Supplementary Figure S11). This is in line
with the recent study from Neumann et al.,
33 who have clearly
demonstrated that Fas activates in parallel the caspases
(8 and 3) and the NF-kB activity and that blocking the caspases
did not impair p65 activation. They have also shown the direct
activation of the IKK complex through Fas-associated death
domain-like interleukin-1b-converting enzyme-like inhibitory
protein (p43-FLIP) formation upon Fas activation, conﬁrming
our ﬁndings on the role of IKK in etoposide-induced NF-kB
activitybyFasrecruitment.Theseresultscoupledwiththerole
of p65 in MB cell death (Figure 2b and c) support the
involvement of a non-apoptotic cell death to enhance
efﬁciently the p53-dependent apoptotic cell death (Figure 3d
and e). Interestingly, a non-apoptotic cell death induced by
Fas receptor stimulation was previously described.
34 We
have observed an induction of autophagy (Supplementary
Figure S4) in the presence of etoposide, which could
potentially be involved in the Fas-NF-kB-induced cell death.
We have shown by qPCR that etoposide could induce other
DRs: DR3, DR4 and DR5 (Figure 4a). As these DR and Fas
are members of the TNF receptor family, a part of machinery
below these receptors is common and we cannot exclude an
additionalroleofthesereceptorsinNF-kBactivation.Thisisin
line with previous reports showing NF-kB activation by
different DRs,
35,36 yet in other systems, the role of NF-kBi n
DRs expression was also described.
37 Moreover, several
studies demonstrated that DRs could have a function in
chemosensitivity, notably in MB.
38,39 In summary, our results
suggest that the DR synthesis and auto-oligomerisation is
likely to be involved in activation of the caspase cascade as
well as in NF-kB activation. In addition, we cannot exclude the
implication of other death domain proteins that could also be
involved in the bridge between p53 and NF-kB. For example,
p53-induced protein with death domain (PIDD) has been
showntobetransactivatedbyp53andtoactivateNF-kBupon
DNA damage through sumoylation and ubiquitination of
upstream NF-kB modulators.
40
The integrity of the p53-Fas-NF-jB signalling is required
for optimal chemosensitivity of MB cells. We have
demonstrated that cells expressing a fully functional
connection between p53 and p65 by Fas receptor production
are the most sensitive to the DNA-damaging agent etoposide
(Figure 6). Indeed, MEB-Med8A, D566-MG and T98G cells
that are impaired in p53 signalling are strongly resistant to
etoposide. Similar results were described in neuroblastoma.
41
Interestingly, in MHH-Med1 and U87MG cells that bear
an apparently normal p53 signalling, but are unable to
further activate p65, we observed an intermediate sensitivity
(Figures 2a and 5a and model Figure 6). The impairment in
p53 signalling in MEB-Med8A cells is at least in part due to the
absence of p53wt and the presence of a truncated isoform.
This isoform could be p53b according to its molecular weight
and migration pattern on western blot.
42 Regarding the
MHH-Med1 cells, we have not been able to identify the
reason why NF-kB phosphorylation and transcription were
completely impaired in these cells even upon the classical
TNFa inducer. The cells display a normal expression pattern of
p65, IkBa and IKK on a western blot compared with other cell
lines (not shown), suggesting a potential mutation upstream in
the receptor adaptor molecules.
In conclusion, our study has depicted a new molecular
mechanism for etoposide-induced cell death that has
clear implications for future clinical treatments. We have
shown the importance in determining biomarkers in tumour
tissues to adapt the chemotherapeutic treatment in a case-
by-case basis. As drug resistance is currently one major
problem in chemotherapy, the elucidation of a genomic
signature for each tumour should allow bypassing some
resistances. Moreover, inducing concomitantly multiple death
pathways may also improve considerably the treatment
efﬁciency.
Materials and Methods
Drugs, antibodies and vectors. Protease and phosphatase inhibitor
cocktails,PFTa,actynomycin-D,cycloheximide,mouseanti-IgG-Cy3conjugateand
mouse anti-Fas antibody (clone DX2, no. F4424) were from Sigma (St Louis, MO,
USA). Etoposide, Wedelolactone, BMS-345541, Bay11-7082, Kp7-6 peptide,
tumour necrosis factor-a (TNFa), Fas ligand ELISA kit and mouse anti-actin
antibody were from Calbiochem (Darmstadt, Germany). Stealth RNAi siRNAs were
from Invitrogen (Carlsbad, CA, USA), and all medium and reagents used in tissue
culture were supplied by Gibco Life Technologies (Carlsbad, CA, USA). Fetal calf
serum was from Harlan Seralab (Loughborough, UK). Luciferin used for
luminometry and luminescence assay was from Biosynth AG (Staad,
Switzerland). Mouse anti-p65 (sc-8008) and mouse anti-p53 (sc-263) antibodies
p53-dependent NF-jB activation by etoposide
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Cell Death and Diseasewere from Santa Cruz Biotechnology Inc. Rabbit anti-p65/Phospho-Ser536
antibody (no. 3031) was from Cell Signalling (Danvers, MA, USA). BCA protein
assay kit and SuperSignal West Dura Extended Duration Chemiluminescent
Substrate were from Pierce Biotechnology (Rockford, IL, USA). Mouse anti-CD95
(clone ZB4, no. 05-338) antibody was from Upstate (Billerica, MA, USA). pNF-kB-
Luc vector was from Stratagene (Santa Clara, CA, USA). pG-p65-RedXP and
pG-IkBa-EGFP were previously described.
4 pCMV-Fas vector was kindly provided by
Dr. T Kanda (National Institute of Infectious Diseases, Tokyo, Japan).
Cell lines and culture. D283-MED, T98G and U87MG cells were purchased
from ATCC (Manassas, VA, USA) and were maintained in minimal essential
medium with Earle’s salts supplemented with 10% fetal calf serum, 1% non-
essential amino acids and 1mM sodium pyruvate. D566-MG and D458-MED were
kindly provided by Professor DD Bigner (Duke UniversityMedical Center, USA) and
were maintained in similar conditions to D283-MED cells. MHH-Med1 cells and
MEB-Med8A cells were kindly provided by Professor T Pietsch (University of Bonn,
Germany) and were maintained in Dulbecco’s modiﬁed Eagle medium
supplemented with 10% fetal calf serum. Cells were seeded twice per week, and
fresh medium was added every 2 days. Cells were grown in a humidiﬁed
atmosphere of 5% CO2 at 371C.
Plasmid and siRNA transfection. FuGENE HD (Roche, Basel,
Switzerland) was diluted in Opti-MEM medium (Invitrogen) before addition of the
plasmid DNA (ratio 8:2). After 15min incubation at RT, the mixture was added on
cells in complete medium. For siRNA transfection, HiPerfect (Qiagen, Hilden,
Germany) was used instead of FuGENE HD.
Viability assay. Cells were plated in 96-well cell culture plates. Twenty-four
hours after plating, cells were treated as indicated for 8–48h. CellTiter 96 Aqueous
One solution (Promega, Madison, WI, USA) was added and was incubated 2h at
371C according to the manufacturer’s indications. The optical densities were
assessed with a plate reader at 492nm.
Confocal microscopy. Confocal microscopy was carried out on transfected
cells in 35mm glass-bottom dishes (Iwaki, Asahi Techno Glass, Tokyo, Japan) in a
humidiﬁedCO2incubatorat371C,5%CO2usingaZeissLSM510(Jena,Germany)
with a  63 Plan Apochromatic oil immersion objective (NA¼1.4). EGFP-tagged
proteins were excited using an Argon ion laser at 488nm. Emitted light was
detected through a 505–550nm bandpass ﬁlter from a 545nm dichroic mirror.
dsRed ﬂuorescence was excited using a green helium–neon laser (543nm) and
was detected through both a 545nm dichroic mirror and a 560nm long-pass ﬁlter.
Data capture was performed with LSM510 version 3 software (Carl Zeiss GmbH,
Jena, Germany) and extraction was carried out with CellTracker v0.6 software
(University of Manchester, UK).
43 Nuclear and cytoplasmic integrated ﬂuorescence
intensity were determined and the nuclear/cytoplasmic ratio was calculated.
Immunoblotting. Total protein was extracted with a lysis buffer (Tris-HCl
pH¼7.5 50mM, EDTA 1mM, EGTA 1mM, Triton X-100 1%, NaF 50mM, sodium
pyrophosphate5mM,sodiumb-glycerophosphate10mM,PMSF0.1mM,protease
inhibitorcocktail1/100andphosphataseinhibitorcocktail1/100).After1hat41Con
a rotating wheel shaker, the lysates were centrifuged X10000 g for 15min at
41C and total protein concentration was measured with BCA assay in the
supernatant. A quantity of 40mg of proteins were resolved by SDS-PAGE (10%
gels) and were transferred onto nitrocellulose membrane. The membranes were
blocked with 5% nonfat dry milk in TBS-T (Tris-HCl pH¼8 10mM, NaCl 100mM,
Tween-20 0.1%) and incubated with appropriate primary antibody (overnight, 41C),
followed by incubation with horseradish peroxidase-conjugated secondary antibody
(1h, RT). SuperSignal West Dura Extended Duration Chemiluminescent Substrate
was used for ECL reaction and the signal was detected and quantiﬁed using G:box
gel doc system (Syngene, Cambridge, UK).
Luminometry. Cells were transfected with a ﬁreﬂy luciferase reporter construct
containing ﬁve repeats of the NF-kB-binding site (pNF-Luc). Twenty-four hours
later, cells were treated as indicated. Cell lysis and luminescence measurements
were performed as described previously
4 using a PerkinElmer EnVision
plate reader (Waltham, MA, USA).
Caspase activity. Cells were plated in 96-well white plates. Caspase-Glo 8
and 3/7 kits (Promega) were used following the manufacturer’s instructions.
Luminescence microscopy. Real-time luminescence imaging was
performed 24h after transfection of cells in 35mm glass-base dishes. Luciferin
(0.5mM)wasaddedintheculturemedium2hbeforedrugtreatment.Luminescence
imaging was carried out in a humidiﬁed incubator (371C, 5% CO2) using a
Hamamatsu VIM photon counting camera attached to a Zeiss Axiovert 135 TV
with a  20 FLUAR objective. Argus-20 control program version 3.53 software
(Hamamatsu Photonics, Hamamatsu City, Japan) was used for image acquisition,
AQM Advance 6.0 software (Kinetic Imaging, Nottingham, UK) was used for image
analysis. Images were acquired using 30min integration time.
Immunocytochemistry. Cells plated in 35mm glass-base dishes were
ﬁxed with paraformaldehyde 4% for 15min at room temperature and treated with
NH4Cl 50mM for 20min at RT. After blocking in PBS – 1% BSA – 0.1% Triton
X-100 for 20min, cells were incubated with anti-Fas antibody (1:500) in blocking
buffer for 1h. After three washes, cells were incubated with an anti-mouse IgG Cy3
conjugate (1:500) for 30min. Cells were imaged using a Zeiss LSM 510 confocal
microscope.
Quantitative RT-PCR. Cellular RNAs were puriﬁed using Qiagen RNeasy
mini kit according to the manufacturer’s instructions. cDNA were synthetised with
QuantiTect Reverse Transcription Kit (Qiagen) and qPCR were performed using
ABI Power SYBR Green PCR master mix (Carlsbad, CA, USA) according the
manufacturer’s instructions. We used an ABI 7500 Fast Real-Time PCR System.
Cyclophilin A was used as a calibrator for the relative ampliﬁcation of genes of
interest calculations.
Primer sequences are as follows: Cyclophilin A forward: GCTTTGGGTCCAG
GAATGG; Cyclophilin A reverse: GTTGTCCACAGTCAGCAATGGT; p65 forward:
AGCGCATCCAGACCAACAA; p65 reverse: TAGTCCCCACGCTGCTCTTC; p53
forward: GGCCCACTTCACCGTACTAA; p53 reverse: GTGGTTTCAAGGCCA
GATGT; mdm2 forward: GGTGGGAGTGATCAAAAGGA; mdm2 reverse: ACACA
GAGCCAGGCTTTCAT; DR3 forward: CACCCTTCTAGCACCTCCTG; DR3
reverse:CCAGCTGTTACCCACCAACT;DR4forward:GCTGCAACCATCAAACTT
CA; DR4 reverse: GGCTATGTTCCCATTGCTGT; DR5 forward: TGCTCTGAT
CACCCAACAAG; DR5 reverse: CAGGTGGACACAATCCCTCT; Fas forward:
GCATCTGGACCCTCCTACCT; Fas reverse: CAGGGCTTATGGCAGAATTG;
IkBa forward: TGGTGTCCTTGGGTGCTGAT; IkBa reverse: . GGCAGTCCGGC
CATTACA; A20 forward: AACGGTGACGGCAATTGC; A20 reverse: TGAA
CGCCCCACATGTACTG.
Statistical analysis. Histograms represent the mean values±S.E.M.
Statistical signiﬁcance was determined by one-way ANOVA followed by a
Bonferroni multiple comparison test. Difference was considered as signiﬁcant
at Po0.01. All these experiments were performed at least three times.
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